# Daiichi Sankyo (4568) Q2 FY2026 earnings

Results filed 2026-10-30 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/daiichi-sankyo/2026-q2/
Press release and documents: https://www.daiichisankyo.com/investors/library/quarterly_result/
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Daiichi Sankyo is scaling Enhertu and Datroway through new first-line approvals, a Summit Therapeutics combination deal and a single global commercialization unit launching April 2027.

Enhertu became the US market leader in first-line HER2-positive metastatic breast cancer and took the top share in adjuvant early breast cancer. Datroway has treated about 9,800 patients globally, roughly 1.4 times the prior quarter, and leads later-line EGFR-mutated lung cancer in the US. New approvals landed across the US, Europe, Japan and China. Non-oncology units such as American Regent and Lixiana were weaker.
Management is centralizing oncology and specialty commercialization into one unit from April 2027, aiming for 20+ indication launches by 2030 and a global top 5 oncology ranking by 2035. It also plans to test Datroway with Summit's ivonescimab. The tension is dependence on two drugs, with a withdrawn US filing for ifinatamab deruxtecan and a fast-moving small cell lung cancer field.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue (six months) | JPY1,167.2 billion | up 19.7% year on year |  |
| Operating profit (six months) | JPY193.8 billion | up 34.4% year on year | GAAP |
| Profit attributable to owners of the Company | JPY151.5 billion | up 15.8% year on year | GAAP |
| Diluted earnings per share (six months) | 83.20 | up from 70.52 a year ago | GAAP |
| Core operating profit (six months) | JPY221.3 billion | up 46.9% year on year | non-GAAP |
| Net cash flows from operating activities (JPY millions) | 50,738 | from (28,311) a year ago | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Oncology Business Unit | JPY422.6 billion | up 54.8% year on year |
| Enhertu global product sales (six months) | 464.5 Bn JPY | up 45.9% year on year |
| Datroway global product sales (six months) | 48.3 Bn JPY | up 207.2% year on year |
| Datroway patients treated since launch | approx. 9,800 | approx. 1.4 times the prior quarter |
| Japan Business Unit | JPY232.7 billion | down 6.9% year on year |
| American Regent Unit | JPY77.9 billion | down 19.5% year on year |
| EU Specialty Business Unit | JPY149.2 billion | up 9.1% year on year |
| ASCA Business Unit | JPY142.5 billion | up 20.9% year on year |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue (JPY millions), unchanged from July | fiscal year ending March 31, 2027 | 2,340,000 |
| Basic earnings per share (JPY) | fiscal year ending March 31, 2027 | 137.94 |
| Capital expenditure (JPY billions) | fiscal 2026 | 200.0 |
| Annual dividend per share (JPY) | fiscal 2026 | JPY100 |

## Key takeaways

1. **Enhertu leads US first-line HER2+ metastatic breast cancer** Enhertu is now the US market leader in HER2+ first-line metastatic breast cancer and holds the No.1 share in HER2+ adjuvant early breast cancer. First-line approvals in China, Japan and Europe in Aug–Sep 2026 widen the addressable base.
2. **Datroway patient base grew 1.4x in a quarter** About 9,800 patients have been treated globally since launch, and new patient starts grew in all promoted indications. It leads later-line EGFR-mutated NSCLC in the US and is gaining early share in first-line TNBC.
3. **Summit deal pairs Datroway with ivonescimab** Daiichi Sankyo and AstraZeneca will study Datroway with Summit's investigational PD-1/VEGF bispecific ivonescimab across multiple solid tumors, starting with first-line TNBC. Costs are shared and each party keeps rights to its own medicine.
4. **One global commercialization unit starts April 2027** Oncology and specialty commercialization will be centralized into 5 regional businesses and 6 global functions. Management cites 20+ anticipated indication launches by 2030 as the reason.
5. **Ifinatamab deruxtecan US filing withdrawn; Enhertu lung data positive** The US application for I-DXd in previously treated small cell lung cancer was voluntarily withdrawn in September 2026. Separately, DESTINY-Lung04 showed Enhertu beating pembrolizumab plus chemotherapy as first-line treatment for HER2-mutant NSCLC.

## Questions

**What were Daiichi Sankyo's main product developments this quarter?** Enhertu and Datroway gained first-line approvals across the US, Europe, Japan and China, and Enhertu became US market leader in first-line HER2+ metastatic breast cancer. Datroway treated about 9,800 patients, 1.4 times the prior quarter.
**What is the Summit Therapeutics collaboration?** Daiichi Sankyo and AstraZeneca will combine Datroway with Summit's investigational PD-1/VEGF antibody ivonescimab, with trial costs shared and each company keeping rights to its own medicine. The first Phase 3 study is in first-line triple-negative breast cancer.
**How is Daiichi Sankyo changing its go-to-market organization?** From April 2027 it will run oncology and specialty commercialization as one global unit, with 5 regional businesses and 6 global functions. The goal is better resource allocation and standardized processes.
**What happened with ifinatamab deruxtecan (I-DXd)?** Daiichi Sankyo voluntarily withdrew its US application for previously treated extensive-stage small cell lung cancer in September 2026, after the filing was accepted with priority review in April. The Phase 3 IDeate-Lung02 readout is expected in FY2027.
**What upcoming pipeline readouts matter for Datroway?** TROPION-Lung15 is expected in FY2026 H2, and AVANZAR in CY2027 H1. TROPION-Lung07, Lung08, Breast03 and Breast05 are also due in FY2027.

## Slides and investor documents

- [FY2026 Q2 Financial Results Presentation Material](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q2_Financial_Results_Presentation_E.pdf) (Slide deck)

